The Next Assembly Line: Vietnam Medical Device Manufacturing Gains Momentum

Hospital system realities shape what gets made, imported, and assembled locally. Vietnam has over 1,300 hospitals and medical facilities serving more than 100 million people, and the private sector has expanded to 384 facilities, or 24% of total hospitals. Yet these private hospitals account for only 5.8% of national bed capacity, and many focus on specialties such as ophthalmology, dentistry, dermatology, cardiology, and oncology, often with fewer than 50 beds. Public hospitals remain dominant at 76% of hospitals, and the Trade.gov guide notes that major urban hospitals can receive up to 60% of the country’s patients and operate beyond intended capacity.

Imports Still Rule, but the Local Footprint Is Expanding

Multiple sources point to strong demand but limited domestic production depth. Vietnam Briefing reports that over 90% of medical equipment has been sourced from abroad, mainly from Japan, Germany, the U.S., China, and Singapore, and that products from these countries accounted for 55% of Vietnam’s total imports of medical equipment. In August 2024, the Director-General of the Drug Administration of Vietnam said the market was thriving at nearly USD 1.7 billion, ranking Vietnam as the eighth-largest market in Asia-Pacific, with a 10.2% CAGR that was lower than the previous 15–18% average. BMI Research also valued the Vietnam medical device market at USD 1.9 billion in 2024.

Against that import-heavy baseline, Vietnam’s manufacturing story is taking shape around what can be produced reliably today. Nexdigm notes that the local manufacturing base for gloves, catheters, syringes, and basic diagnostics is expanding, supported by rising domestic FDI and government incentives targeting a 10–15% private hospital bed share by 2025. The same source adds that several industrial zones now host medical consumable factories with monthly output in the tens of thousands of units. Market participants named in Taiwan News include Stryker Corporation Vietnam, USM Healthcare Medical Devices Factory JSC, Medical Devices and Biomaterial Plant Joint Stock Company, and Omron Healthcare Vietnam, reflecting a mix of local operations and international brands building footholds.

The next layer of opportunity depends on moving up from consumables into more regulated, higher-precision device components. IndexBox’s Vietnam cell culture sampling devices analysis says the country is characterized by near-total import dependence for finished devices in that segment, with local capability limited to low-value assembly or distribution. It also states that Vietnam lacks a deep, tiered supply chain for medical-grade polymers and high-precision cleanroom molding infrastructure required for core component manufacturing, so any local assembly is typically limited to simple kitting of imported components under strict license and quality oversight. Still, demand signals are clear: Trade.gov reports that much existing equipment in public hospitals is obsolete and needs replacement, and the Ministry of Health estimates nearly 40,000 Vietnamese consumers spend about USD 2 billion annually traveling abroad for medical services—creating a practical case for scaling vietnam medical device manufacturing capacity where feasible.